[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"blog-post-retatrutide-liver-damage-myths-fr":3},{"_path":4,"_dir":5,"_draft":6,"_partial":6,"_locale":7,"title":8,"description":7,"cat":9,"icon":10,"accent":11,"date":12,"dateLabel":13,"read":14,"author":15,"image":16,"body":17,"_type":2416,"_id":2417,"_source":2418,"_file":2419,"_stem":2420,"_extension":2421},"\u002Fblog\u002Ffr\u002Fretatrutide-liver-damage-myths","fr",false,"","Rétatrutide et foie : le fact-check","Fact-check","tabler:microscope","#F2A93B","2026-06-27","Juin 2026","20 min","myPeptides Team","\u002Fassets\u002Freta_hero.png",{"type":18,"children":19,"toc":2394},"root",[20,124,131,143,317,322,328,334,339,348,398,417,423,462,480,486,491,499,535,561,567,572,580,600,665,671,676,684,731,737,742,785,791,796,801,805,811,816,822,842,870,876,897,932,938,972,1012,1018,1070,1090,1126,1144,1237,1254,1346,1351,1357,1369,1415,1421,1433,1460,1466,1498,1504,1518,1524,1550,1576,1582],{"type":21,"tag":22,"props":23,"children":24},"element","disclaimer",{},[25,38,70,80,99,116],{"type":21,"tag":26,"props":27,"children":28},"p",{},[29,36],{"type":21,"tag":30,"props":31,"children":32},"em",{},[33],{"type":34,"value":35},"text","Ceci relève de l'opinion et du commentaire scientifique — pas d'un avis médical, ni d'une affirmation factuelle concernant qui que ce soit au-delà de ce que nos sources établissent.",{"type":34,"value":37}," Cet article traite, au titre de l'intérêt public et du commentaire loyal, d'affirmations médicales qu'une personnalité publique a choisi de diffuser auprès d'un large public.",{"type":21,"tag":26,"props":39,"children":40},{},[41,47,49,54,56,61,63,68],{"type":21,"tag":42,"props":43,"children":44},"strong",{},[45],{"type":34,"value":46},"Faits contre opinion.",{"type":34,"value":48}," Là où nous énonçons des faits vérifiables — le statut d'une licence professionnelle, la propriété d'une entreprise, les termes employés dans des documents et vidéos accessibles au public —, nous renvoyons aux sources primaires pour que vous puissiez vérifier par vous-même. Tout ce que nous présentons comme une ",{"type":21,"tag":30,"props":50,"children":51},{},[52],{"type":34,"value":53},"appréciation",{"type":34,"value":55},", une ",{"type":21,"tag":30,"props":57,"children":58},{},[59],{"type":34,"value":60},"lecture des données",{"type":34,"value":62}," ou notre ",{"type":21,"tag":30,"props":64,"children":65},{},[66],{"type":34,"value":67},"point de vue",{"type":34,"value":69}," relève de l'opinion et du commentaire loyal sur des propos tenus publiquement. Nous ne prétendons pas connaître les intentions privées de quiconque ; lorsque nous évoquons une motivation ou un effet, nous le décrivons tel que nous le percevons, non comme un fait établi.",{"type":21,"tag":26,"props":71,"children":72},{},[73,78],{"type":21,"tag":42,"props":74,"children":75},{},[76],{"type":34,"value":77},"Les sources peuvent être incomplètes.",{"type":34,"value":79}," Toutes les informations réunies ici proviennent de sources accessibles au public ; elles sont présentées de bonne foi et au mieux de nos connaissances au moment de la rédaction. Les registres publics et les rapports de tiers peuvent être incomplets, évoluer ou être remplacés ; il se peut que des éléments de contexte nous aient échappé, et que nous nous trompions sur des points de détail.",{"type":21,"tag":26,"props":81,"children":82},{},[83,88,90,97],{"type":21,"tag":42,"props":84,"children":85},{},[86],{"type":34,"value":87},"Droit de réponse et de rectification.",{"type":34,"value":89}," Si vous êtes cité ici et estimez qu'une affirmation factuelle est inexacte ou dépassée — ou si vous souhaitez ajouter votre point de vue —, contactez-nous via nos ",{"type":21,"tag":91,"props":92,"children":94},"a",{"href":93},"\u002Flegal-notice",[95],{"type":34,"value":96},"mentions légales",{"type":34,"value":98}," : nous examinerons votre demande et corrigerons ou mettrons à jour l'article si cela se justifie. Nous accueillons volontiers les corrections documentées.",{"type":21,"tag":26,"props":100,"children":101},{},[102,107,109,114],{"type":21,"tag":42,"props":103,"children":104},{},[105],{"type":34,"value":106},"Pas un avis médical — et pas une incitation à utiliser quoi que ce soit.",{"type":34,"value":108}," Rien ici ne vous dit quoi faire de votre propre corps, et rien ici ne cautionne ni ne vous invite à vous procurer, doser ou utiliser du rétatrutide ou toute autre substance — dont plusieurs sont expérimentales et non approuvées pour un usage humain dans de nombreux pays. Les chiffres d'essais que nous citons décrivent des résultats rapportés dans des études publiées ; ce ne sont ni des promesses de résultat ni des recommandations de dosage. Si vous envisagez ou utilisez l'une de ces substances, ",{"type":21,"tag":42,"props":110,"children":111},{},[112],{"type":34,"value":113},"consultez le médecin en qui vous avez le moins de méfiance — en personne —",{"type":34,"value":115}," avant d'agir sur la foi de ce que vous lisez en ligne, ici ou ailleurs.",{"type":21,"tag":26,"props":117,"children":118},{},[119],{"type":21,"tag":30,"props":120,"children":121},{},[122],{"type":34,"value":123},"Dernière mise à jour : 27 juin 2026. Cet article relève de l'opinion et du commentaire et pourra être révisé à mesure que de nouvelles informations seront disponibles.",{"type":21,"tag":125,"props":126,"children":128},"h2",{"id":127},"lessentiel",[129],{"type":34,"value":130},"L'essentiel",{"type":21,"tag":26,"props":132,"children":133},{},[134,136,141],{"type":34,"value":135},"Une vidéo de 45 minutes intitulée ",{"type":21,"tag":30,"props":137,"children":138},{},[139],{"type":34,"value":140},"« Mega Dosing vs Micro Dosing Retatrutide: Which Damages Your Liver More? »",{"type":34,"value":142}," soutient que le rétatrutide abîme sournoisement votre foie et votre pancréas, sauf si vous suivez un protocole de dosage bien précis — que le présentateur vend ensuite, en même temps que les peptides eux-mêmes. Nous avons vérifié. En bref :",{"type":21,"tag":144,"props":145,"children":146},"ul",{},[147,184,234,258,298],{"type":21,"tag":148,"props":149,"children":150},"li",{},[151,156,158,163,165,173,175,182],{"type":21,"tag":42,"props":152,"children":153},{},[154],{"type":34,"value":155},"Le messager.",{"type":34,"value":157}," « Dr » Trevor Bachmeyer n'est pas médecin. C'est un ancien chiropracteur dont la licence californienne (DC 29377) a été ",{"type":21,"tag":42,"props":159,"children":160},{},[161],{"type":34,"value":162},"révoquée avec effet au 8 juillet 2020",{"type":34,"value":164},", comme le consigne le ",{"type":21,"tag":91,"props":166,"children":170},{"href":167,"rel":168},"https:\u002F\u002Fwww.chiro.ca.gov\u002Fabout_us\u002Fmeetings\u002F20201029_materials.pdf",[169],"nofollow",[171],{"type":34,"value":172},"California Board of Chiropractic Examiners",{"type":34,"value":174},". Cette même vidéo aiguille les spectateurs vers son coaching payant et vers sa propre boutique de peptides de recherche, ",{"type":21,"tag":91,"props":176,"children":179},{"href":177,"rel":178},"https:\u002F\u002Felitebiogenix.com\u002F",[169],[180],{"type":34,"value":181},"EliteBiogenix",{"type":34,"value":183},".",{"type":21,"tag":148,"props":185,"children":186},{},[187,192,194,199,201,206,208,215,217,224,225,232],{"type":21,"tag":42,"props":188,"children":189},{},[190],{"type":34,"value":191},"« Le glucagon inonde votre corps de graisse. »",{"type":34,"value":193}," Trompeur. Chez l'humain, le glucagon physiologique ne dégrade ",{"type":21,"tag":42,"props":195,"children":196},{},[197],{"type":34,"value":198},"pas",{"type":34,"value":200}," directement la graisse corporelle (le tissu adipeux blanc) — il stimule l'oxydation des graisses ",{"type":21,"tag":30,"props":202,"children":203},{},[204],{"type":34,"value":205},"à l'intérieur du foie",{"type":34,"value":207}," (",{"type":21,"tag":91,"props":209,"children":212},{"href":210,"rel":211},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F32132708\u002F",[169],[213],{"type":34,"value":214},"Perry et al., Nature 2020",{"type":34,"value":216}," ; ",{"type":21,"tag":91,"props":218,"children":221},{"href":219,"rel":220},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC9576180\u002F",[169],[222],{"type":34,"value":223},"Vasileva et al., 2022",{"type":34,"value":216},{"type":21,"tag":91,"props":226,"children":229},{"href":227,"rel":228},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F11344211\u002F",[169],[230],{"type":34,"value":231},"Gravholt et al., 2001",{"type":34,"value":233},").",{"type":21,"tag":148,"props":235,"children":236},{},[237,242,244,249,250,257],{"type":21,"tag":42,"props":238,"children":239},{},[240],{"type":34,"value":241},"« Une hausse de la lipase veut dire que votre pancréas lâche. »",{"type":34,"value":243}," En grande partie faux. Les hausses enzymatiques légères et sans symptôme sont fréquentes et bénignes ; de vastes jeux de données d'essais ne montrent ",{"type":21,"tag":42,"props":245,"children":246},{},[247],{"type":34,"value":248},"aucune augmentation des pancréatites aiguës",{"type":34,"value":207},{"type":21,"tag":91,"props":251,"children":254},{"href":252,"rel":253},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F28476871\u002F",[169],[255],{"type":34,"value":256},"Steinberg et al., Diabetes Care 2017",{"type":34,"value":233},{"type":21,"tag":148,"props":259,"children":260},{},[261,266,268,273,275,280,282,289,291,296],{"type":21,"tag":42,"props":262,"children":263},{},[264],{"type":34,"value":265},"« Le rétatrutide surcharge et abîme le foie. »",{"type":34,"value":267}," Tout le contraire des données. Dans l'essai de phase 2 sur la graisse hépatique, il a ",{"type":21,"tag":42,"props":269,"children":270},{},[271],{"type":34,"value":272},"réduit la graisse du foie jusqu'à 86 %",{"type":34,"value":274},", et ",{"type":21,"tag":42,"props":276,"children":277},{},[278],{"type":34,"value":279},"~93 % des patients sous la dose la plus forte ont normalisé",{"type":34,"value":281}," leur graisse hépatique (",{"type":21,"tag":91,"props":283,"children":286},{"href":284,"rel":285},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC11271400\u002F",[169],[287],{"type":34,"value":288},"Sanyal et al., Nature Medicine 2024",{"type":34,"value":290},"). Le rétatrutide est justement développé ",{"type":21,"tag":30,"props":292,"children":293},{},[294],{"type":34,"value":295},"comme traitement",{"type":34,"value":297}," de la stéatose hépatique.",{"type":21,"tag":148,"props":299,"children":300},{},[301,306,308,315],{"type":21,"tag":42,"props":302,"children":303},{},[304],{"type":34,"value":305},"Ce qu'il vise juste.",{"type":34,"value":307}," Deux choses : ne pas tout arrêter en panique pour un chiffre de lipase isolé, et le fait qu'une perte de poids rapide coûte réellement du muscle (",{"type":21,"tag":91,"props":309,"children":312},{"href":310,"rel":311},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC12471476\u002F",[169],[313],{"type":34,"value":314},"Koceva et al., 2025",{"type":34,"value":316},"). Des arguments valables emballés dans une frayeur qui, elle, ne l'est pas.",{"type":21,"tag":26,"props":318,"children":319},{},[320],{"type":34,"value":321},"Le tableau complet — et la science derrière chacun des points ci-dessus — suit. L'analyse approfondie, en fin d'article, est une introduction sourcée à toute cette classe de médicaments — écrite pour que vous puissiez vérifier nos dires, pas seulement nous croire sur parole.",{"type":21,"tag":323,"props":324,"children":327},"youtube",{"id":325,"title":326},"gb-XEtsMr-w","The video this article examines — Bachmeyer on retatrutide dosing",[],{"type":21,"tag":125,"props":329,"children":331},{"id":330},"qui-avance-cette-affirmation",[332],{"type":34,"value":333},"Qui avance cette affirmation",{"type":21,"tag":26,"props":335,"children":336},{},[337],{"type":34,"value":338},"Avant la science, la source. Il se présente comme « Dr Trevor Bachmeyer, The Spartan » et « World's #1 Health Authority » auprès d'un public de plusieurs centaines de milliers de personnes. Deux faits vérifiables comptent.",{"type":21,"tag":26,"props":340,"children":341},{},[342],{"type":21,"tag":343,"props":344,"children":347},"img",{"alt":345,"src":346},"Comment une peur sanitaire peut être canalisée vers la vente d'un produit","\u002Fassets\u002Freta_funnel.png",[],{"type":21,"tag":26,"props":349,"children":350},{},[351,353,358,360,365,367,371,373,379,380,387,389,396],{"type":34,"value":352},"Premièrement, ",{"type":21,"tag":42,"props":354,"children":355},{},[356],{"type":34,"value":357},"ce n'est pas un médecin.",{"type":34,"value":359}," C'est un ancien ",{"type":21,"tag":42,"props":361,"children":362},{},[363],{"type":34,"value":364},"chiropracteur",{"type":34,"value":366},", et même cette licence-là a disparu : la licence californienne DC 29377 a été ",{"type":21,"tag":42,"props":368,"children":369},{},[370],{"type":34,"value":162},{"type":34,"value":372}," par le California Board of Chiropractic Examiners. La mesure est consignée dans les propres documents de l'ordre (",{"type":21,"tag":91,"props":374,"children":376},{"href":167,"rel":375},[169],[377],{"type":34,"value":378},"documents de séance, 29 oct. 2020",{"type":34,"value":216},{"type":21,"tag":91,"props":381,"children":384},{"href":382,"rel":383},"https:\u002F\u002Fwww.chiro.ca.gov\u002Fenforcement\u002Factions.shtml",[169],[385],{"type":34,"value":386},"Sanctions disciplinaires définitives",{"type":34,"value":388},") et vérifiable via l'",{"type":21,"tag":91,"props":390,"children":393},{"href":391,"rel":392},"https:\u002F\u002Fsearch.dca.ca.gov\u002F",[169],[394],{"type":34,"value":395},"annuaire des licences",{"type":34,"value":397}," de l'État — le lecteur peut consulter les documents mis en lien pour le détail exact des constats. Il continue de se présenter comme « Dr », un usage qui, à nos yeux, invite le lecteur à lui prêter une qualification médicale actuelle qu'il n'a pas.",{"type":21,"tag":26,"props":399,"children":400},{},[401,403,408,410,415],{"type":34,"value":402},"Deuxièmement, ",{"type":21,"tag":42,"props":404,"children":405},{},[406],{"type":34,"value":407},"il vend l'objet même de ses conseils.",{"type":34,"value":409}," La vidéo dirige les spectateurs vers un abonnement de coaching payant « Black Card » et vers ",{"type":21,"tag":91,"props":411,"children":413},{"href":177,"rel":412},[169],[414],{"type":34,"value":181},{"type":34,"value":416},", sa boutique de peptides de recherche et de SARM « réservés à la recherche in vitro ». Autrement dit, la personne qui vous avertit que le rétatrutide vous abîmera à moins de le doser correctement vend aussi le mode d'emploi du dosage et les peptides eux-mêmes. Ce n'est pas disqualifiant en soi — mais c'est précisément le conflit d'intérêts qu'un spectateur avisé devrait garder en tête, et c'est la raison d'être de cet article.",{"type":21,"tag":125,"props":418,"children":420},{"id":419},"ce-quil-avance-vraiment-en-toute-équité",[421],{"type":34,"value":422},"Ce qu'il avance vraiment — en toute équité",{"type":21,"tag":26,"props":424,"children":425},{},[426,428,433,435,440,442,447,449,454,456,461],{"type":34,"value":427},"Il serait facile de caricaturer sa position, alors soyons précis. La description de sa propre vidéo affirme que ",{"type":21,"tag":30,"props":429,"children":430},{},[431],{"type":34,"value":432},"« retatrutide itself doesn't directly cause liver or pancreatic damage; irresponsible dosing and poor monitoring causes biological damage. »",{"type":34,"value":434}," Sa liste de chapitres s'enchaîne ainsi : ",{"type":21,"tag":30,"props":436,"children":437},{},[438],{"type":34,"value":439},"« Glucagon Fat Flood → Pancreas Overload → Fatty Liver Cascade → Insulin Resistance Spiral »",{"type":34,"value":441},", avant de basculer vers un ",{"type":21,"tag":30,"props":443,"children":444},{},[445],{"type":34,"value":446},"« Damage Control Protocol »",{"type":34,"value":448},", des ",{"type":21,"tag":30,"props":450,"children":451},{},[452],{"type":34,"value":453},"« Safe Dosing Rules »",{"type":34,"value":455}," et ",{"type":21,"tag":30,"props":457,"children":458},{},[459],{"type":34,"value":460},"« Use It Responsibly »",{"type":34,"value":183},{"type":21,"tag":26,"props":463,"children":464},{},[465,467,471,473,478],{"type":34,"value":466},"Sa thèse n'est donc ",{"type":21,"tag":42,"props":468,"children":469},{},[470],{"type":34,"value":198},{"type":34,"value":472}," « ce médicament est un poison, fuyez-le ». C'est « ce médicament vous abîmera ",{"type":21,"tag":30,"props":474,"children":475},{},[476],{"type":34,"value":477},"sauf si vous le dosez à ma façon",{"type":34,"value":479}," ». C'est plus subtil, ça paraît plus crédible, et c'est bien plus vendeur — et c'est ce que nous vérifions. Le problème n'est pas qu'il invente de fausses études. C'est qu'il bâtit un mécanisme effrayant à partir de termes réels, alors que les données d'essais ne soutiennent pas la partie qui fait peur.",{"type":21,"tag":125,"props":481,"children":483},{"id":482},"affirmation-1-l-inondation-de-graisse-par-le-glucagon",[484],{"type":34,"value":485},"Affirmation 1 : l'« inondation de graisse par le glucagon »",{"type":21,"tag":26,"props":487,"children":488},{},[489],{"type":34,"value":490},"Son moteur, c'est la composante glucagon du rétatrutide : elle libérerait un déluge de graisse — des acides gras libres jaillissant de vos réserves adipeuses et submergeant le foie et le pancréas.",{"type":21,"tag":26,"props":492,"children":493},{},[494],{"type":21,"tag":343,"props":495,"children":498},{"alt":496,"src":497},"Le glucagon stimule l'oxydation des graisses dans le foie, pas dans la graisse corporelle","\u002Fassets\u002Freta_glucagon.png",[],{"type":21,"tag":26,"props":500,"children":501},{},[502,504,509,511,517,519,525,526,533],{"type":34,"value":503},"C'est le plus vieux mythe de la physiologie du glucagon. Oui, le glucagon est un puissant signal brûle-graisse — ",{"type":21,"tag":42,"props":505,"children":506},{},[507],{"type":34,"value":508},"mais dans le foie, pas dans votre graisse corporelle.",{"type":34,"value":510}," Le récepteur du glucagon est densément exprimé sur les cellules hépatiques et à peine présent sur les cellules graisseuses humaines. Quand des chercheurs ont supprimé le récepteur du glucagon spécifiquement dans le tissu adipeux de souris, rien n'a bougé : ni leur métabolisme des graisses, ni leur poids, ni leurs acides gras libres circulants (",{"type":21,"tag":91,"props":512,"children":514},{"href":219,"rel":513},[169],[515],{"type":34,"value":516},"Vasileva et al., AJP-Endocrinology 2022",{"type":34,"value":518},"). Chez l'humain, porter le glucagon à des niveaux physiologiques n'augmente pas du tout la lipolyse dans la graisse abdominale (",{"type":21,"tag":91,"props":520,"children":522},{"href":227,"rel":521},[169],[523],{"type":34,"value":524},"Gravholt et al., JCEM 2001",{"type":34,"value":216},{"type":21,"tag":91,"props":527,"children":530},{"href":528,"rel":529},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F1991802\u002F",[169],[531],{"type":34,"value":532},"Jensen et al., JCEM 1991",{"type":34,"value":534},"). L'effet lipolytique n'apparaît qu'en éprouvette, à des concentrations supraphysiologiques que la circulation sanguine n'atteint jamais.",{"type":21,"tag":26,"props":536,"children":537},{},[538,540,544,546,551,552,559],{"type":34,"value":539},"Ce que fait réellement le glucagon, c'est stimuler l'oxydation des graisses ",{"type":21,"tag":42,"props":541,"children":542},{},[543],{"type":34,"value":205},{"type":34,"value":545}," — via une voie cAMP\u002FPKA et un mécanisme calcique qui activent la dégradation hépatique des graisses (",{"type":21,"tag":91,"props":547,"children":549},{"href":210,"rel":548},[169],[550],{"type":34,"value":214},{"type":34,"value":216},{"type":21,"tag":91,"props":553,"children":556},{"href":554,"rel":555},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F38300523\u002F",[169],[557],{"type":34,"value":558},"Kajani et al., Physiological Reviews 2024",{"type":34,"value":560},") — et augmenter la dépense énergétique de tout l'organisme. L'image d'un glucagon qui « fait fondre » la graisse du ventre et en inonde vos organes est un artefact d'éprouvette, pas de la physiologie humaine. Les fondations de son « déluge » sont fissurées dès le premier chapitre.",{"type":21,"tag":125,"props":562,"children":564},{"id":563},"affirmation-2-la-surcharge-du-pancréas",[565],{"type":34,"value":566},"Affirmation 2 : la « surcharge » du pancréas",{"type":21,"tag":26,"props":568,"children":569},{},[570],{"type":34,"value":571},"Vient ensuite la lipase élevée, présentée comme la preuve que votre pancréas est poussé vers la défaillance.",{"type":21,"tag":26,"props":573,"children":574},{},[575],{"type":21,"tag":343,"props":576,"children":579},{"alt":577,"src":578},"Une hausse légère de la lipase traduit une fuite enzymatique sans gravité, pas une destruction du pancréas","\u002Fassets\u002Freta_pancreas.png",[],{"type":21,"tag":26,"props":581,"children":582},{},[583,585,590,592,599],{"type":34,"value":584},"La réalité, plus terne : les hausses légères et sans symptôme de la lipase et de l'amylase sont ",{"type":21,"tag":42,"props":586,"children":587},{},[588],{"type":34,"value":589},"fréquentes et généralement sans danger",{"type":34,"value":591}," avec cette classe de médicaments. Elles traduisent des cellules acineuses stimulées mais intactes, qui laissent fuir un peu d'enzyme dans le sang — une « fuite » physiologique, pas l'organe en train de se digérer lui-même. On connaît même le mécanisme récepteur en cause : les récepteurs du GLP-1 siègent sur les cellules acineuses du pancréas et les incitent à libérer de l'enzyme, en tissu sain, sans le moindre dommage (",{"type":21,"tag":91,"props":593,"children":596},{"href":594,"rel":595},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC4698438\u002F",[169],[597],{"type":34,"value":598},"Hou… Williams et al., AJP-GI 2016",{"type":34,"value":233},{"type":21,"tag":26,"props":601,"children":602},{},[603,605,610,611,616,618,625,627,632,634,641,643,648,650,654,656,663],{"type":34,"value":604},"Et les critères de jugement durs sont rassurants. Dans les grands programmes d'essais du liraglutide, l'amylase et la lipase ont augmenté modérément ",{"type":21,"tag":42,"props":606,"children":607},{},[608],{"type":34,"value":609},"sans prédire de pancréatite aiguë",{"type":34,"value":207},{"type":21,"tag":91,"props":612,"children":614},{"href":252,"rel":613},[169],[615],{"type":34,"value":256},{"type":34,"value":617},"). Une revue systématique « vivante » de 2026, regroupant 31 essais contrôlés contre placebo et plus de 40 000 patients, a constaté des taux de pancréatite quasiment identiques sous médicament et sous placebo (odds ratio ≈ 0,99) — même si, en toute honnêteté, il s'agit encore d'un ",{"type":21,"tag":91,"props":619,"children":622},{"href":620,"rel":621},"https:\u002F\u002Fwww.medrxiv.org\u002Fcontent\u002F10.64898\u002F2026.03.19.26348844v1",[169],[623],{"type":34,"value":624},"preprint",{"type":34,"value":626}," non encore relu par les pairs. Une analyse de 2024 a même rapporté ",{"type":21,"tag":42,"props":628,"children":629},{},[630],{"type":34,"value":631},"moins",{"type":34,"value":633}," d'épisodes de pancréatite récurrente chez les patients à haut risque sous GLP-1 (",{"type":21,"tag":91,"props":635,"children":638},{"href":636,"rel":637},"https:\u002F\u002Fwww.endocrine.org\u002Fnews-and-advocacy\u002Fnews-room\u002F2024\u002Fendo-2024-press-nassar",[169],[639],{"type":34,"value":640},"Nassar et al., ENDO 2024 — résumé de congrès",{"type":34,"value":642},"), sans doute parce que ces médicaments corrigent les déclencheurs sous-jacents. Point crucial : la pancréatite aiguë est un diagnostic clinique — les critères d'Atlanta révisés exigent une vraie douleur ",{"type":21,"tag":30,"props":644,"children":645},{},[646],{"type":34,"value":647},"plus",{"type":34,"value":649}," une lipase supérieure à trois fois la limite supérieure de la normale ",{"type":21,"tag":30,"props":651,"children":652},{},[653],{"type":34,"value":647},{"type":34,"value":655}," de l'imagerie (",{"type":21,"tag":91,"props":657,"children":660},{"href":658,"rel":659},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F23100216\u002F",[169],[661],{"type":34,"value":662},"Banks et al., Gut 2013",{"type":34,"value":664},"). Un chiffre de laboratoire isolé ne suffit pas, et le saut de « votre lipase est haute » à « votre pancréas est en surcharge et se dirige vers la défaillance » n'est pas étayé.",{"type":21,"tag":125,"props":666,"children":668},{"id":667},"affirmation-3-la-cascade-de-stéatose-hépatique",[669],{"type":34,"value":670},"Affirmation 3 : la « cascade de stéatose hépatique »",{"type":21,"tag":26,"props":672,"children":673},{},[674],{"type":34,"value":675},"C'est l'inversion centrale, et celle qu'il importe le plus de bien comprendre.",{"type":21,"tag":26,"props":677,"children":678},{},[679],{"type":21,"tag":343,"props":680,"children":683},{"alt":681,"src":682},"Le rétatrutide réduit fortement la graisse hépatique dans les essais cliniques","\u002Fassets\u002Freta_liverfat.png",[],{"type":21,"tag":26,"props":685,"children":686},{},[687,689,694,696,701,703,708,710,715,717,722,724,729],{"type":34,"value":688},"Il présente le rétatrutide comme une molécule qui surcharge et abîme le foie — une « cascade de stéatose hépatique », une « surcharge du foie ». Les données d'essais montrent ",{"type":21,"tag":42,"props":690,"children":691},{},[692],{"type":34,"value":693},"exactement l'inverse.",{"type":34,"value":695}," Dans l'étude de phase 2 sur la graisse hépatique, le rétatrutide a réduit la graisse du foie de façon dose-dépendante : à 48 semaines, ",{"type":21,"tag":42,"props":697,"children":698},{},[699],{"type":34,"value":700},"−81,7 %",{"type":34,"value":702}," à 8 mg et ",{"type":21,"tag":42,"props":704,"children":705},{},[706],{"type":34,"value":707},"−86,0 %",{"type":34,"value":709}," à 12 mg, contre −4,6 % sous placebo. Dans le groupe recevant la dose la plus forte, ",{"type":21,"tag":42,"props":711,"children":712},{},[713],{"type":34,"value":714},"environ 93 % des patients ont vu leur graisse hépatique passer sous le seuil des 5 %",{"type":34,"value":716}," — soit, en pratique, une normalisation médicale de leur stéatose (",{"type":21,"tag":91,"props":718,"children":720},{"href":284,"rel":719},[169],[721],{"type":34,"value":288},{"type":34,"value":723},"). C'est l'une des plus fortes baisses de graisse hépatique rapportées à ce jour dans le développement clinique de la molécule. Le rétatrutide n'est pas un danger hépatique caché ; il est développé ",{"type":21,"tag":42,"props":725,"children":726},{},[727],{"type":34,"value":728},"comme traitement de la stéatose hépatique (MASLD)",{"type":34,"value":730},". Son effet net sur le foie, en essais contrôlés, est profondément protecteur — l'exact contraire de la cascade qu'il décrit.",{"type":21,"tag":125,"props":732,"children":734},{"id":733},"ce-quil-vise-juste",[735],{"type":34,"value":736},"Ce qu'il vise juste",{"type":21,"tag":26,"props":738,"children":739},{},[740],{"type":34,"value":741},"Un fact-check honnête souligne les coups au but, pas seulement les ratés — et deux de ses arguments de fond sont légitimes.",{"type":21,"tag":26,"props":743,"children":744},{},[745,747,752,754,759,761,766,767,774,776,783],{"type":34,"value":746},"Il a raison de dire qu'il ne faut ",{"type":21,"tag":42,"props":748,"children":749},{},[750],{"type":34,"value":751},"pas paniquer et arrêter le traitement pour une hausse de lipase isolée et sans symptôme",{"type":34,"value":753}," ; cela correspond bien à ce que suggèrent les recommandations de gastro-entérologie. Et il a raison de dire qu'une perte de poids rapide sous ces médicaments coûte de la ",{"type":21,"tag":42,"props":755,"children":756},{},[757],{"type":34,"value":758},"masse maigre",{"type":34,"value":760}," — environ un quart, voire près de la moitié du poids perdu peut être de la masse non grasse, en bonne partie du muscle (",{"type":21,"tag":91,"props":762,"children":764},{"href":310,"rel":763},[169],[765],{"type":34,"value":314},{"type":34,"value":216},{"type":21,"tag":91,"props":768,"children":771},{"href":769,"rel":770},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC11450469\u002F",[169],[772],{"type":34,"value":773},"Tinsley et al., 2024",{"type":34,"value":775},"), raison pour laquelle l'apport en protéines et la musculation ont leur place dans tout plan sérieux (",{"type":21,"tag":91,"props":777,"children":780},{"href":778,"rel":779},"https:\u002F\u002Fdiabetesjournals.org\u002Fcare\u002Farticle\u002F47\u002F10\u002F1718\u002F154535\u002F",[169],[781],{"type":34,"value":782},"Locatelli et al., Diabetes Care 2024",{"type":34,"value":784},"). Ces points sont réels. Le problème, c'est l'emballage qui les entoure.",{"type":21,"tag":125,"props":786,"children":788},{"id":787},"le-schéma-récurrent",[789],{"type":34,"value":790},"Le schéma récurrent",{"type":21,"tag":26,"props":792,"children":793},{},[794],{"type":34,"value":795},"Selon notre appréciation, le schéma est ici classique : on emploie un vocabulaire réel pour se donner de l'autorité ; on assemble une « cascade de dommages » effrayante que, à notre lecture des données d'essais, les preuves ne soutiennent pas ; on qualifie les autres voix de « désinformation » ; et le remède proposé est un protocole payant assorti de peptides vendus par la boutique de l'auteur. Nous ne prétendons pas connaître ses intentions — nous décrivons l'effet tel que nous le percevons, et chacun peut soupeser lui-même le contexte commercial.",{"type":21,"tag":26,"props":797,"children":798},{},[799],{"type":34,"value":800},"Le rétatrutide est un médicament expérimental sérieux, doté d'un vrai profil d'effets indésirables (surtout gastro-intestinaux, dose-dépendants, à leur maximum pendant la montée en dose) et de vraies questions ouvertes sur l'usage au long cours et la perte musculaire. Il mérite de la prudence et un médecin prescripteur. Il ne mérite pas un récit fabriqué de défaillance d'organe signé par quelqu'un qui vend l'antidote.",{"type":21,"tag":802,"props":803,"children":804},"hr",{},[],{"type":21,"tag":125,"props":806,"children":808},{"id":807},"le-tableau-scientifique-complet",[809],{"type":34,"value":810},"Le tableau scientifique complet",{"type":21,"tag":26,"props":812,"children":813},{},[814],{"type":34,"value":815},"La partie ci-dessus, c'est le verdict. Celle-ci, c'est le travail de fond : une introduction sourcée à ce que font réellement ces médicaments, pour que vous puissiez juger les affirmations par vous-même plutôt que de croire quiconque sur parole — nous ou lui. C'est dense, à dessein.",{"type":21,"tag":125,"props":817,"children":819},{"id":818},"de-la-nafld-à-la-masld",[820],{"type":34,"value":821},"De la NAFLD à la MASLD",{"type":21,"tag":26,"props":823,"children":824},{},[825,827,832,834,841],{"type":34,"value":826},"Pendant des décennies, l'accumulation de graisse dans le foie sans consommation excessive d'alcool s'appelait la stéatose hépatique non alcoolique (NAFLD) — aujourd'hui la maladie chronique du foie la plus répandue au monde, touchant environ 30 à 38 % des adultes. En 2023, un consensus international l'a rebaptisée ",{"type":21,"tag":42,"props":828,"children":829},{},[830],{"type":34,"value":831},"MASLD — stéatose hépatique associée à une dysfonction métabolique",{"type":34,"value":833}," — pour placer la cause métabolique au premier plan plutôt que de définir la maladie par ce qu'elle n'est pas (",{"type":21,"tag":91,"props":835,"children":838},{"href":836,"rel":837},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC10653297\u002F",[169],[839],{"type":34,"value":840},"Rinella et al., 2023",{"type":34,"value":233},{"type":21,"tag":26,"props":843,"children":844},{},[845,847,852,854,861,863,868],{"type":34,"value":846},"La progression se décrit par un ",{"type":21,"tag":42,"props":848,"children":849},{},[850],{"type":34,"value":851},"modèle des « coups multiples » (multiple-hit)",{"type":34,"value":853}," : le premier coup, c'est la graisse qui s'accumule dans les cellules du foie, ce qui rend ensuite l'organe vulnérable à d'autres agressions — stress oxydatif, dysfonction mitochondriale, dysbiose de l'axe intestin-foie, inflammation (",{"type":21,"tag":91,"props":855,"children":858},{"href":856,"rel":857},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F26823198\u002F",[169],[859],{"type":34,"value":860},"Buzzetti et al., 2016",{"type":34,"value":862},"). Le spectre va de la simple stéatose à la stéatohépatite (MASH) avec inflammation et lésions cellulaires, puis à la fibrose, la cirrhose et le cancer du foie. Le moteur de cette progression est la ",{"type":21,"tag":42,"props":864,"children":865},{},[866],{"type":34,"value":867},"lipotoxicité",{"type":34,"value":869}," — non pas le triglycéride inerte lui-même, mais des intermédiaires lipidiques toxiques comme les céramides et les diacylglycérols, qui endommagent la machinerie cellulaire et déclenchent des voies inflammatoires.",{"type":21,"tag":125,"props":871,"children":873},{"id":872},"résistance-hépatique-sélective-à-linsuline",[874],{"type":34,"value":875},"Résistance hépatique sélective à l'insuline",{"type":21,"tag":26,"props":877,"children":878},{},[879,881,888,889,896],{"type":34,"value":880},"L'une des idées les plus importantes ici, développée en grande partie par Samuel et Shulman, résout un paradoxe : pourquoi un foie diabétique ignore le signal de l'insuline lui demandant de cesser de fabriquer du glucose, tout en obéissant encore à son signal lui demandant de fabriquer de la graisse (",{"type":21,"tag":91,"props":882,"children":885},{"href":883,"rel":884},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC4701542\u002F",[169],[886],{"type":34,"value":887},"Samuel & Shulman, JCI 2016",{"type":34,"value":216},{"type":21,"tag":91,"props":890,"children":893},{"href":891,"rel":892},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC5762395\u002F",[169],[894],{"type":34,"value":895},"Cell Metabolism 2018",{"type":34,"value":233},{"type":21,"tag":26,"props":898,"children":899},{},[900,902,907,909,914,916,923,925,930],{"type":34,"value":901},"Le mécanisme : à mesure que la graisse s'accumule dans le foie, le ",{"type":21,"tag":42,"props":903,"children":904},{},[905],{"type":34,"value":906},"diacylglycérol",{"type":34,"value":908}," s'y accumule à son tour et active une enzyme (PKCε) qui grippe le signal proximal de l'insuline. L'insuline ne parvient plus à freiner la production de glucose — d'où la montée de la glycémie — mais la machinerie de fabrication de graisse, elle, continue de tourner, alimentée par un substrat brut et des taux d'insuline élevés. Ajoutez à cela un tissu adipeux résistant qui déverse des acides gras libres directement dans le foie, et vous obtenez une boucle d'accumulation de graisse qui s'auto-entretient. Les études isotopiques chiffrent cet afflux : chez les patients atteints de stéatose, environ ",{"type":21,"tag":42,"props":910,"children":911},{},[912],{"type":34,"value":913},"59 % des triglycérides stockés dans le foie proviennent des acides gras libres circulants",{"type":34,"value":915}," (lipolyse périphérique), ~26 % de la lipogenèse de novo et ~15 % de l'alimentation (",{"type":21,"tag":91,"props":917,"children":920},{"href":918,"rel":919},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC1087172\u002F",[169],[921],{"type":34,"value":922},"Donnelly et al., JCI 2005",{"type":34,"value":924},"). C'est là la vraie biologie que la vidéo effleure — et c'est précisément pourquoi un médicament qui ",{"type":21,"tag":30,"props":926,"children":927},{},[928],{"type":34,"value":929},"réduit",{"type":34,"value":931}," cet afflux de graisse aide au lieu de nuire.",{"type":21,"tag":125,"props":933,"children":935},{"id":934},"ce-que-fait-vraiment-le-glucagon-et-le-mythe-de-la-graisse-blanche",[936],{"type":34,"value":937},"Ce que fait vraiment le glucagon — et le mythe de la graisse blanche",{"type":21,"tag":26,"props":939,"children":940},{},[941,943,948,950,955,956,963,964,970],{"type":34,"value":942},"Le glucagon, longtemps réduit au simple contraire de l'insuline, est aujourd'hui compris comme un régulateur global du métabolisme énergétique et lipidique. Sa cible principale est le foie, où il déclenche la libération de glucose et, surtout, ",{"type":21,"tag":42,"props":944,"children":945},{},[946],{"type":34,"value":947},"stimule l'oxydation des graisses et freine la synthèse de nouvelles graisses",{"type":34,"value":949}," via une voie cAMP\u002FPKA et un mécanisme de libération du calcium qui active la dégradation hépatique des graisses (",{"type":21,"tag":91,"props":951,"children":953},{"href":210,"rel":952},[169],[954],{"type":34,"value":214},{"type":34,"value":216},{"type":21,"tag":91,"props":957,"children":960},{"href":958,"rel":959},"https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Fphysiology\u002Farticles\u002F10.3389\u002Ffphys.2019.00413\u002Ffull",[169],[961],{"type":34,"value":962},"Galsgaard et al., 2019",{"type":34,"value":216},{"type":21,"tag":91,"props":965,"children":967},{"href":554,"rel":966},[169],[968],{"type":34,"value":969},"Kajani et al., 2024",{"type":34,"value":971},"). C'est justement cette « combustion des graisses » hépatique qui a poussé les concepteurs du médicament à greffer un signal glucagon sur le rétatrutide.",{"type":21,"tag":26,"props":973,"children":974},{},[975,977,982,984,989,991,996,997,1003,1005,1010],{"type":34,"value":976},"Mais — et c'est là que le mythe se corrige — cette action est ",{"type":21,"tag":42,"props":978,"children":979},{},[980],{"type":34,"value":981},"hépatique, pas périphérique.",{"type":34,"value":983}," De vieilles expériences in vitro montraient que des cellules graisseuses isolées pouvaient dégrader de la graisse lorsqu'on les baignait dans du glucagon, mais seulement à des concentrations 10 à 100 fois supérieures à tout ce que le corps produit. Les travaux modernes tranchent : supprimez le récepteur du glucagon du tissu adipeux et le métabolisme lipidique ne change pas (",{"type":21,"tag":91,"props":985,"children":987},{"href":219,"rel":986},[169],[988],{"type":34,"value":223},{"type":34,"value":990},") ; administrez à des humains du glucagon à dose physiologique et la lipolyse de la graisse abdominale ne bronche pas (",{"type":21,"tag":91,"props":992,"children":994},{"href":227,"rel":993},[169],[995],{"type":34,"value":231},{"type":34,"value":216},{"type":21,"tag":91,"props":998,"children":1000},{"href":528,"rel":999},[169],[1001],{"type":34,"value":1002},"Jensen et al., 1991",{"type":34,"value":1004},"). La perte de poids sous les médicaments contenant du glucagon vient de la baisse de l'appétit, de la hausse de la dépense énergétique et de l'oxydation des graisses ",{"type":21,"tag":42,"props":1006,"children":1007},{},[1008],{"type":34,"value":1009},"dans le foie",{"type":34,"value":1011}," — pas d'un glucagon qui dissoudrait la graisse de votre ventre pour en inonder vos organes.",{"type":21,"tag":125,"props":1013,"children":1015},{"id":1014},"le-saut-poly-agoniste-du-sémaglutide-au-rétatrutide",[1016],{"type":34,"value":1017},"Le saut poly-agoniste : du sémaglutide au rétatrutide",{"type":21,"tag":26,"props":1019,"children":1020},{},[1021,1023,1028,1030,1037,1039,1044,1045,1052,1054,1061,1062,1069],{"type":34,"value":1022},"Les médicaments incrétiniques sont des mimétiques d'hormones intestinales, conçus pour résister à une dégradation rapide et donc durer plus longtemps. La première vague fut celle des mono-agonistes du GLP-1 : le sémaglutide a produit environ ",{"type":21,"tag":42,"props":1024,"children":1025},{},[1026],{"type":34,"value":1027},"14,9 %",{"type":34,"value":1029}," de perte de poids moyenne dans son essai pivot sur l'obésité (",{"type":21,"tag":91,"props":1031,"children":1034},{"href":1032,"rel":1033},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F33567185\u002F",[169],[1035],{"type":34,"value":1036},"STEP 1, Wilding et al., NEJM 2021",{"type":34,"value":1038},"). Est ensuite venu le double agonisme GLP-1\u002FGIP : le tirzépatide a atteint jusqu'à ",{"type":21,"tag":42,"props":1040,"children":1041},{},[1042],{"type":34,"value":1043},"20,9 %",{"type":34,"value":207},{"type":21,"tag":91,"props":1046,"children":1049},{"href":1047,"rel":1048},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F35658024\u002F",[169],[1050],{"type":34,"value":1051},"SURMOUNT-1, Jastreboff et al., NEJM 2022",{"type":34,"value":1053},"). Pour la physiologie de leur action conjuguée, voir ",{"type":21,"tag":91,"props":1055,"children":1058},{"href":1056,"rel":1057},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F39160334\u002F",[169],[1059],{"type":34,"value":1060},"Holst, Nature Metabolism 2024",{"type":34,"value":455},{"type":21,"tag":91,"props":1063,"children":1066},{"href":1064,"rel":1065},"https:\u002F\u002Fdom-pubs.onlinelibrary.wiley.com\u002Fdoi\u002F10.1111\u002Fdom.14496",[169],[1067],{"type":34,"value":1068},"Nauck et al., 2021",{"type":34,"value":183},{"type":21,"tag":26,"props":1071,"children":1072},{},[1073,1075,1080,1081,1088],{"type":34,"value":1074},"Le rétatrutide (LY3437943) va un cran plus loin : une seule molécule qui active les récepteurs ",{"type":21,"tag":42,"props":1076,"children":1077},{},[1078],{"type":34,"value":1079},"GLP-1, GIP et glucagon",{"type":34,"value":207},{"type":21,"tag":91,"props":1082,"children":1085},{"href":1083,"rel":1084},"https:\u002F\u002Fclinicaltrials.gov\u002Fstudy\u002FNCT04881760",[169],[1086],{"type":34,"value":1087},"essai NCT04881760",{"type":34,"value":1089},"). La composante glucagon apporte l'oxydation hépatique des graisses et la dépense énergétique ; les composantes GLP-1 et GIP apportent l'effet coupe-faim et le soutien à l'insuline et — c'est décisif — annulent la tendance du glucagon à faire monter la glycémie.",{"type":21,"tag":26,"props":1091,"children":1092},{},[1093,1095,1100,1102,1109,1111,1117,1119,1124],{"type":34,"value":1094},"Une précision sur les noms : les données de ",{"type":21,"tag":42,"props":1096,"children":1097},{},[1098],{"type":34,"value":1099},"phase 2",{"type":34,"value":1101}," qui suivent proviennent de ",{"type":21,"tag":91,"props":1103,"children":1106},{"href":1104,"rel":1105},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F37366315\u002F",[169],[1107],{"type":34,"value":1108},"Jastreboff et al., NEJM 2023",{"type":34,"value":1110}," et de la ",{"type":21,"tag":91,"props":1112,"children":1114},{"href":284,"rel":1113},[169],[1115],{"type":34,"value":1116},"sous-étude MASLD, Sanyal et al., Nature Medicine 2024",{"type":34,"value":1118},". « TRIUMPH » désigne le programme ultérieur de ",{"type":21,"tag":30,"props":1120,"children":1121},{},[1122],{"type":34,"value":1123},"phase 3",{"type":34,"value":1125}," — alors ne laissez personne présenter des chiffres de phase 2 comme des résultats de TRIUMPH-1.",{"type":21,"tag":26,"props":1127,"children":1128},{},[1129,1134,1136,1142],{"type":21,"tag":42,"props":1130,"children":1131},{},[1132],{"type":34,"value":1133},"Variation de poids à 48 semaines",{"type":34,"value":1135}," (phase 2, n=338 ; ",{"type":21,"tag":91,"props":1137,"children":1139},{"href":1104,"rel":1138},[169],[1140],{"type":34,"value":1141},"Jastreboff et al., 2023",{"type":34,"value":1143},") :",{"type":21,"tag":1145,"props":1146,"children":1147},"table",{},[1148,1167],{"type":21,"tag":1149,"props":1150,"children":1151},"thead",{},[1152],{"type":21,"tag":1153,"props":1154,"children":1155},"tr",{},[1156,1162],{"type":21,"tag":1157,"props":1158,"children":1159},"th",{},[1160],{"type":34,"value":1161},"Dose hebdomadaire",{"type":21,"tag":1157,"props":1163,"children":1164},{},[1165],{"type":34,"value":1166},"Variation de poids moyenne",{"type":21,"tag":1168,"props":1169,"children":1170},"tbody",{},[1171,1185,1198,1211,1224],{"type":21,"tag":1153,"props":1172,"children":1173},{},[1174,1180],{"type":21,"tag":1175,"props":1176,"children":1177},"td",{},[1178],{"type":34,"value":1179},"Placebo",{"type":21,"tag":1175,"props":1181,"children":1182},{},[1183],{"type":34,"value":1184},"−2,1 %",{"type":21,"tag":1153,"props":1186,"children":1187},{},[1188,1193],{"type":21,"tag":1175,"props":1189,"children":1190},{},[1191],{"type":34,"value":1192},"Rétatrutide 1 mg",{"type":21,"tag":1175,"props":1194,"children":1195},{},[1196],{"type":34,"value":1197},"−8,7 %",{"type":21,"tag":1153,"props":1199,"children":1200},{},[1201,1206],{"type":21,"tag":1175,"props":1202,"children":1203},{},[1204],{"type":34,"value":1205},"Rétatrutide 4 mg",{"type":21,"tag":1175,"props":1207,"children":1208},{},[1209],{"type":34,"value":1210},"−17,1 %",{"type":21,"tag":1153,"props":1212,"children":1213},{},[1214,1219],{"type":21,"tag":1175,"props":1215,"children":1216},{},[1217],{"type":34,"value":1218},"Rétatrutide 8 mg",{"type":21,"tag":1175,"props":1220,"children":1221},{},[1222],{"type":34,"value":1223},"−22,8 %",{"type":21,"tag":1153,"props":1225,"children":1226},{},[1227,1232],{"type":21,"tag":1175,"props":1228,"children":1229},{},[1230],{"type":34,"value":1231},"Rétatrutide 12 mg",{"type":21,"tag":1175,"props":1233,"children":1234},{},[1235],{"type":34,"value":1236},"−24,2 %",{"type":21,"tag":26,"props":1238,"children":1239},{},[1240,1245,1247,1253],{"type":21,"tag":42,"props":1241,"children":1242},{},[1243],{"type":34,"value":1244},"Variation de la graisse hépatique à 48 semaines",{"type":34,"value":1246}," (sous-étude MASLD, n=98 ; ",{"type":21,"tag":91,"props":1248,"children":1250},{"href":284,"rel":1249},[169],[1251],{"type":34,"value":1252},"Sanyal et al., 2024",{"type":34,"value":1143},{"type":21,"tag":1145,"props":1255,"children":1256},{},[1257,1277],{"type":21,"tag":1149,"props":1258,"children":1259},{},[1260],{"type":21,"tag":1153,"props":1261,"children":1262},{},[1263,1267,1272],{"type":21,"tag":1157,"props":1264,"children":1265},{},[1266],{"type":34,"value":1161},{"type":21,"tag":1157,"props":1268,"children":1269},{},[1270],{"type":34,"value":1271},"Variation relative de la graisse hépatique",{"type":21,"tag":1157,"props":1273,"children":1274},{},[1275],{"type":34,"value":1276},"Graisse hépatique normalisée (\u003C 5 %)",{"type":21,"tag":1168,"props":1278,"children":1279},{},[1280,1297,1314,1330],{"type":21,"tag":1153,"props":1281,"children":1282},{},[1283,1287,1292],{"type":21,"tag":1175,"props":1284,"children":1285},{},[1286],{"type":34,"value":1179},{"type":21,"tag":1175,"props":1288,"children":1289},{},[1290],{"type":34,"value":1291},"−4,6 %",{"type":21,"tag":1175,"props":1293,"children":1294},{},[1295],{"type":34,"value":1296},"0 %",{"type":21,"tag":1153,"props":1298,"children":1299},{},[1300,1304,1309],{"type":21,"tag":1175,"props":1301,"children":1302},{},[1303],{"type":34,"value":1192},{"type":21,"tag":1175,"props":1305,"children":1306},{},[1307],{"type":34,"value":1308},"−51,3 %",{"type":21,"tag":1175,"props":1310,"children":1311},{},[1312],{"type":34,"value":1313},"> 50 %",{"type":21,"tag":1153,"props":1315,"children":1316},{},[1317,1321,1325],{"type":21,"tag":1175,"props":1318,"children":1319},{},[1320],{"type":34,"value":1218},{"type":21,"tag":1175,"props":1322,"children":1323},{},[1324],{"type":34,"value":700},{"type":21,"tag":1175,"props":1326,"children":1327},{},[1328],{"type":34,"value":1329},"—",{"type":21,"tag":1153,"props":1331,"children":1332},{},[1333,1337,1341],{"type":21,"tag":1175,"props":1334,"children":1335},{},[1336],{"type":34,"value":1231},{"type":21,"tag":1175,"props":1338,"children":1339},{},[1340],{"type":34,"value":707},{"type":21,"tag":1175,"props":1342,"children":1343},{},[1344],{"type":34,"value":1345},"~93 %",{"type":21,"tag":26,"props":1347,"children":1348},{},[1349],{"type":34,"value":1350},"Près d'un quart du poids corporel envolé en moins d'un an, dans des proportions jusque-là atteintes seulement par la chirurgie bariatrique — et une stéatose hépatique normalisée chez plus de neuf patients sur dix à la dose la plus forte. Voilà les données qu'un récit de « surcharge du foie » est bien obligé d'ignorer.",{"type":21,"tag":125,"props":1352,"children":1354},{"id":1353},"effets-gastro-intestinaux-et-la-question-de-lanesthésie",[1355],{"type":34,"value":1356},"Effets gastro-intestinaux et la question de l'anesthésie",{"type":21,"tag":26,"props":1358,"children":1359},{},[1360,1362,1367],{"type":34,"value":1361},"Le prix de cette efficacité est surtout gastro-intestinal. Un vidage gastrique ralenti et un signal de nausée au niveau du tronc cérébral font des nausées, des vomissements, des diarrhées et de la constipation les effets indésirables les plus courants — dose-dépendants, les plus marqués pendant la montée en dose, et généralement passagers (",{"type":21,"tag":91,"props":1363,"children":1365},{"href":1104,"rel":1364},[169],[1366],{"type":34,"value":1141},{"type":34,"value":1368},"). Une titration lente (commencer par de faibles doses) est la parade habituelle.",{"type":21,"tag":26,"props":1370,"children":1371},{},[1372,1374,1381,1382,1389,1391,1398,1400,1407,1409,1413],{"type":34,"value":1373},"Une conséquence concrète a suscité un vrai débat médical : parce que ces médicaments ralentissent le vidage gastrique, les aliments peuvent stagner plus longtemps dans l'estomac, augmentant le risque de résidus gastriques avant une anesthésie et un risque théorique d'inhalation. Les méta-analyses constatent bien un contenu gastrique résiduel nettement plus élevé chez les utilisateurs (",{"type":21,"tag":91,"props":1375,"children":1378},{"href":1376,"rel":1377},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC11264430\u002F",[169],[1379],{"type":34,"value":1380},"do Nascimento et al., 2024",{"type":34,"value":216},{"type":21,"tag":91,"props":1383,"children":1386},{"href":1384,"rel":1385},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F40133086\u002F",[169],[1387],{"type":34,"value":1388},"Tan et al., 2025",{"type":34,"value":1390},"), même si les inhalations réelles restent rares (",{"type":21,"tag":91,"props":1392,"children":1395},{"href":1393,"rel":1394},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC11651700\u002F",[169],[1396],{"type":34,"value":1397},"Jalleh et al., JCEM 2024",{"type":34,"value":1399},"). Les sociétés d'anesthésie recommandent désormais de suspendre le médicament avant une intervention programmée (",{"type":21,"tag":91,"props":1401,"children":1404},{"href":1402,"rel":1403},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F37982170\u002F",[169],[1405],{"type":34,"value":1406},"recommandations de l'ASA, 2024",{"type":34,"value":1408},"). Voilà une réserve légitime et bien caractérisée — et, fait notable, ce n'est ",{"type":21,"tag":30,"props":1410,"children":1411},{},[1412],{"type":34,"value":198},{"type":34,"value":1414}," celle sur laquelle la vidéo se concentre.",{"type":21,"tag":125,"props":1416,"children":1418},{"id":1417},"le-pancréas-comment-il-fonctionne-et-la-question-de-la-lipase",[1419],{"type":34,"value":1420},"Le pancréas : comment il fonctionne, et la question de la lipase",{"type":21,"tag":26,"props":1422,"children":1423},{},[1424,1426,1432],{"type":34,"value":1425},"Plus de 90 % du pancréas est un tissu exocrine — des cellules acineuses qui fabriquent les enzymes digestives. Elles stockent des précurseurs enzymatiques inactifs et les libèrent au bon moment ; c'est l'activation prématurée à l'intérieur de la cellule qui définit la vraie pancréatite. Des récepteurs du GLP-1 sont présents sur ces cellules acineuses, si bien que les médicaments stimulent la libération d'enzymes comme un effet normal, médié par récepteur (",{"type":21,"tag":91,"props":1427,"children":1429},{"href":594,"rel":1428},[169],[1430],{"type":34,"value":1431},"Hou… Williams et al., 2016",{"type":34,"value":233},{"type":21,"tag":26,"props":1434,"children":1435},{},[1436,1438,1443,1445,1451,1453,1458],{"type":34,"value":1437},"Voilà pourquoi les légères élévations de la lipase et de l'amylase sont si fréquentes sous traitement — et pourquoi elles sont le plus souvent sans signification. Il s'agit d'une ",{"type":21,"tag":30,"props":1439,"children":1440},{},[1441],{"type":34,"value":1442},"fuite",{"type":34,"value":1444}," d'enzyme stimulée, pas d'une destruction tissulaire. Les données d'essais (ci-dessus) montrent que ces hausses ne prédisent pas la pancréatite (",{"type":21,"tag":91,"props":1446,"children":1448},{"href":252,"rel":1447},[169],[1449],{"type":34,"value":1450},"Steinberg et al., 2017",{"type":34,"value":1452},"), et les données regroupées ne montrent aucun surrisque de pancréatite par rapport au placebo. Le risque de fond, lui, existe bel et bien, mais il tient au profil des patients : les personnes obèses et diabétiques de type 2 ont un risque de pancréatite de base plus élevé, du fait de calculs biliaires et de triglycérides élevés, indépendamment de tout médicament. Traiter ces facteurs est vraisemblablement la raison pour laquelle certaines données montrent une récidive ",{"type":21,"tag":42,"props":1454,"children":1455},{},[1456],{"type":34,"value":1457},"réduite",{"type":34,"value":1459}," sous GLP-1.",{"type":21,"tag":125,"props":1461,"children":1463},{"id":1462},"la-vraie-réserve-la-perte-de-masse-maigre",[1464],{"type":34,"value":1465},"La vraie réserve : la perte de masse maigre",{"type":21,"tag":26,"props":1467,"children":1468},{},[1469,1471,1476,1478,1483,1484,1489,1491,1497],{"type":34,"value":1470},"S'il est un avertissement qui mérite le temps d'antenne que la vidéo consacre à des atteintes d'organes imaginaires, c'est bien celui-ci. Dans l'ensemble des essais sur les incrétines, une part substantielle du poids perdu est de la ",{"type":21,"tag":42,"props":1472,"children":1473},{},[1474],{"type":34,"value":1475},"masse non grasse",{"type":34,"value":1477}," — environ 25 à 40 %, en bonne partie du muscle squelettique (",{"type":21,"tag":91,"props":1479,"children":1481},{"href":310,"rel":1480},[169],[1482],{"type":34,"value":314},{"type":34,"value":216},{"type":21,"tag":91,"props":1485,"children":1487},{"href":769,"rel":1486},[169],[1488],{"type":34,"value":773},{"type":34,"value":1490},"). Ce n'est pas propre à ces médicaments — toute perte de poids importante et rapide produit le même effet — mais perdre du muscle abaisse le métabolisme de base (ce qui nourrit la reprise de poids après l'arrêt), réduit la sensibilité à l'insuline et accroît la fragilité et le risque de chute chez les personnes âgées. La solution fondée sur les preuves n'a rien de glamour : un apport suffisant en protéines et une musculation progressive en parallèle du médicament (",{"type":21,"tag":91,"props":1492,"children":1494},{"href":778,"rel":1493},[169],[1495],{"type":34,"value":1496},"Locatelli et al., 2024",{"type":34,"value":233},{"type":21,"tag":125,"props":1499,"children":1501},{"id":1500},"nouvelles-frontières-immunométabolisme-et-cancer",[1502],{"type":34,"value":1503},"Nouvelles frontières : immunométabolisme et cancer",{"type":21,"tag":26,"props":1505,"children":1506},{},[1507,1509,1516],{"type":34,"value":1508},"Enfin, un aperçu de la direction que prend la science. L'obésité entretient une inflammation chronique et « épuise » sur le plan métabolique les cellules immunitaires qui combattent les tumeurs. Des travaux préliminaires suggèrent que les GLP-1 peuvent en partie inverser cela : dans des modèles de souris obèses atteintes d'un cancer du poumon, un agoniste du GLP-1 a ralenti la croissance tumorale et amélioré l'environnement immunitaire antitumoral — un effet observé uniquement chez les animaux obèses (",{"type":21,"tag":91,"props":1510,"children":1513},{"href":1511,"rel":1512},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F40857107\u002F",[169],[1514],{"type":34,"value":1515},"Pachimatla… Sanghvi et al., JCI Insight 2025",{"type":34,"value":1517},"). C'est préclinique et précoce, mais cela laisse entrevoir que corriger la dysfonction métabolique pourrait avoir des bénéfices bien au-delà de la balance.",{"type":21,"tag":125,"props":1519,"children":1521},{"id":1520},"le-verdict-honnête",[1522],{"type":34,"value":1523},"Le verdict honnête",{"type":21,"tag":26,"props":1525,"children":1526},{},[1527,1529,1534,1536,1541,1543,1548],{"type":34,"value":1528},"Mettez les preuves bout à bout et le tableau est l'inverse de celui de la vidéo. En essais contrôlés, le rétatrutide ",{"type":21,"tag":42,"props":1530,"children":1531},{},[1532],{"type":34,"value":1533},"fait chuter",{"type":34,"value":1535}," spectaculairement la graisse hépatique, ",{"type":21,"tag":42,"props":1537,"children":1538},{},[1539],{"type":34,"value":1540},"n'augmente pas",{"type":34,"value":1542}," le risque de pancréatite et ",{"type":21,"tag":42,"props":1544,"children":1545},{},[1546],{"type":34,"value":1547},"ne dissout pas",{"type":34,"value":1549}," votre graisse corporelle via un quelconque déluge de glucagon. Les vraies mises en garde — perte musculaire, effets gastro-intestinaux, interaction avec l'anesthésie, et le fait brut qu'un produit du marché gris n'est pas réglementé et ne correspond peut-être pas à ce qu'annonce l'étiquette — sont précisément celles qu'un vendeur de peptides a le moins intérêt à souligner.",{"type":21,"tag":26,"props":1551,"children":1552},{},[1553,1555,1559,1561,1567,1569,1575],{"type":34,"value":1554},"Si vous envisagez tout cela ou l'utilisez déjà, la bonne démarche n'est pas une vidéo de 45 minutes et un bouton de paiement. C'est un bilan sanguin, un vrai prescripteur et des attentes honnêtes. Si quelque chose vous semble anormal, ",{"type":21,"tag":42,"props":1556,"children":1557},{},[1558],{"type":34,"value":113},{"type":34,"value":1560}," avant de faire confiance à un protocole vendu par la personne qui vous a diagnostiqué sur YouTube. Pour les doses d'essai telles que rapportées dans la littérature publiée, consultez notre ",{"type":21,"tag":91,"props":1562,"children":1564},{"href":1563},"\u002Fglp1\u002Fretatrutide",[1565],{"type":34,"value":1566},"fiche rétatrutide",{"type":34,"value":1568}," ; et pour comprendre d'abord cette classe de médicaments, commencez par ",{"type":21,"tag":91,"props":1570,"children":1572},{"href":1571},"\u002Fwhat-are-peptides",[1573],{"type":34,"value":1574},"ce que sont les peptides",{"type":34,"value":183},{"type":21,"tag":125,"props":1577,"children":1579},{"id":1578},"références",[1580],{"type":34,"value":1581},"Références",{"type":21,"tag":1583,"props":1584,"children":1585},"ol",{},[1586,1620,1652,1669,1691,1713,1737,1761,1784,1806,1829,1852,1877,1906,1929,1951,1973,1995,2017,2039,2061,2084,2106,2128,2150,2172,2193,2215,2237,2258,2280,2302,2320,2336,2353,2370],{"type":21,"tag":148,"props":1587,"children":1588},{},[1589,1591,1596,1598,1603,1605,1611,1613],{"type":34,"value":1590},"Jastreboff AM, Kaplan LM, Frías JP, et al. ",{"type":21,"tag":42,"props":1592,"children":1593},{},[1594],{"type":34,"value":1595},"Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.",{"type":34,"value":1597}," ",{"type":21,"tag":30,"props":1599,"children":1600},{},[1601],{"type":34,"value":1602},"N Engl J Med",{"type":34,"value":1604}," 2023. ",{"type":21,"tag":91,"props":1606,"children":1608},{"href":1104,"rel":1607},[169],[1609],{"type":34,"value":1610},"PubMed",{"type":34,"value":1612}," · ",{"type":21,"tag":91,"props":1614,"children":1617},{"href":1615,"rel":1616},"https:\u002F\u002Fwww.nejm.org\u002Fdoi\u002Ffull\u002F10.1056\u002FNEJMoa2301972",[169],[1618],{"type":34,"value":1619},"NEJM",{"type":21,"tag":148,"props":1621,"children":1622},{},[1623,1625,1630,1631,1636,1638,1644,1645],{"type":34,"value":1624},"Sanyal AJ, et al. ",{"type":21,"tag":42,"props":1626,"children":1627},{},[1628],{"type":34,"value":1629},"Triple hormone receptor agonist retatrutide for MASLD: a randomized phase 2a trial.",{"type":34,"value":1597},{"type":21,"tag":30,"props":1632,"children":1633},{},[1634],{"type":34,"value":1635},"Nature Medicine",{"type":34,"value":1637}," 2024. ",{"type":21,"tag":91,"props":1639,"children":1641},{"href":284,"rel":1640},[169],[1642],{"type":34,"value":1643},"Texte intégral PMC",{"type":34,"value":1612},{"type":21,"tag":91,"props":1646,"children":1649},{"href":1647,"rel":1648},"https:\u002F\u002Fwww.nature.com\u002Farticles\u002Fs41591-024-03018-2",[169],[1650],{"type":34,"value":1651},"Nature",{"type":21,"tag":148,"props":1653,"children":1654},{},[1655,1657,1662,1663],{"type":34,"value":1656},"Enregistrement de l'essai d'obésité de phase 2 du rétatrutide. ",{"type":21,"tag":30,"props":1658,"children":1659},{},[1660],{"type":34,"value":1661},"ClinicalTrials.gov",{"type":34,"value":1597},{"type":21,"tag":91,"props":1664,"children":1666},{"href":1083,"rel":1665},[169],[1667],{"type":34,"value":1668},"NCT04881760",{"type":21,"tag":148,"props":1670,"children":1671},{},[1672,1674,1679,1680,1684,1686],{"type":34,"value":1673},"Perry RJ, et al. ",{"type":21,"tag":42,"props":1675,"children":1676},{},[1677],{"type":34,"value":1678},"Glucagon stimulates gluconeogenesis by INSP3R1-mediated hepatic lipolysis.",{"type":34,"value":1597},{"type":21,"tag":30,"props":1681,"children":1682},{},[1683],{"type":34,"value":1651},{"type":34,"value":1685}," 2020. ",{"type":21,"tag":91,"props":1687,"children":1689},{"href":210,"rel":1688},[169],[1690],{"type":34,"value":1610},{"type":21,"tag":148,"props":1692,"children":1693},{},[1694,1696,1701,1702,1707,1708],{"type":34,"value":1695},"Kajani S, et al. ",{"type":21,"tag":42,"props":1697,"children":1698},{},[1699],{"type":34,"value":1700},"Hepatic glucagon action: beyond glucose mobilization.",{"type":34,"value":1597},{"type":21,"tag":30,"props":1703,"children":1704},{},[1705],{"type":34,"value":1706},"Physiological Reviews",{"type":34,"value":1637},{"type":21,"tag":91,"props":1709,"children":1711},{"href":554,"rel":1710},[169],[1712],{"type":34,"value":1610},{"type":21,"tag":148,"props":1714,"children":1715},{},[1716,1718,1723,1724,1729,1731],{"type":34,"value":1717},"Galsgaard KD, et al. ",{"type":21,"tag":42,"props":1719,"children":1720},{},[1721],{"type":34,"value":1722},"Glucagon Receptor Signaling and Lipid Metabolism.",{"type":34,"value":1597},{"type":21,"tag":30,"props":1725,"children":1726},{},[1727],{"type":34,"value":1728},"Front Physiol",{"type":34,"value":1730}," 2019. ",{"type":21,"tag":91,"props":1732,"children":1734},{"href":958,"rel":1733},[169],[1735],{"type":34,"value":1736},"Texte intégral",{"type":21,"tag":148,"props":1738,"children":1739},{},[1740,1742,1747,1748,1753,1755],{"type":34,"value":1741},"Vasileva A, et al. ",{"type":21,"tag":42,"props":1743,"children":1744},{},[1745],{"type":34,"value":1746},"Glucagon receptor signaling at white adipose tissue does not regulate lipolysis.",{"type":34,"value":1597},{"type":21,"tag":30,"props":1749,"children":1750},{},[1751],{"type":34,"value":1752},"Am J Physiol Endocrinol Metab",{"type":34,"value":1754}," 2022. ",{"type":21,"tag":91,"props":1756,"children":1758},{"href":219,"rel":1757},[169],[1759],{"type":34,"value":1760},"PMC",{"type":21,"tag":148,"props":1762,"children":1763},{},[1764,1766,1771,1772,1777,1779],{"type":34,"value":1765},"Gravholt CH, et al. ",{"type":21,"tag":42,"props":1767,"children":1768},{},[1769],{"type":34,"value":1770},"Physiological levels of glucagon do not influence lipolysis in abdominal adipose tissue.",{"type":34,"value":1597},{"type":21,"tag":30,"props":1773,"children":1774},{},[1775],{"type":34,"value":1776},"JCEM",{"type":34,"value":1778}," 2001. ",{"type":21,"tag":91,"props":1780,"children":1782},{"href":227,"rel":1781},[169],[1783],{"type":34,"value":1610},{"type":21,"tag":148,"props":1785,"children":1786},{},[1787,1789,1794,1795,1799,1801],{"type":34,"value":1788},"Jensen MD, et al. ",{"type":21,"tag":42,"props":1790,"children":1791},{},[1792],{"type":34,"value":1793},"Effects of glucagon on free fatty acid metabolism in humans.",{"type":34,"value":1597},{"type":21,"tag":30,"props":1796,"children":1797},{},[1798],{"type":34,"value":1776},{"type":34,"value":1800}," 1991. ",{"type":21,"tag":91,"props":1802,"children":1804},{"href":528,"rel":1803},[169],[1805],{"type":34,"value":1610},{"type":21,"tag":148,"props":1807,"children":1808},{},[1809,1811,1816,1817,1822,1824],{"type":34,"value":1810},"Hou Y, Ernst SA, Heidenreich K, Williams JA. ",{"type":21,"tag":42,"props":1812,"children":1813},{},[1814],{"type":34,"value":1815},"GLP-1 receptor is present in pancreatic acinar cells and regulates amylase secretion.",{"type":34,"value":1597},{"type":21,"tag":30,"props":1818,"children":1819},{},[1820],{"type":34,"value":1821},"Am J Physiol Gastrointest Liver Physiol",{"type":34,"value":1823}," 2016. ",{"type":21,"tag":91,"props":1825,"children":1827},{"href":594,"rel":1826},[169],[1828],{"type":34,"value":1760},{"type":21,"tag":148,"props":1830,"children":1831},{},[1832,1834,1839,1840,1845,1847],{"type":34,"value":1833},"Steinberg WM, et al. ",{"type":21,"tag":42,"props":1835,"children":1836},{},[1837],{"type":34,"value":1838},"Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide (LEADER).",{"type":34,"value":1597},{"type":21,"tag":30,"props":1841,"children":1842},{},[1843],{"type":34,"value":1844},"Diabetes Care",{"type":34,"value":1846}," 2017. ",{"type":21,"tag":91,"props":1848,"children":1850},{"href":252,"rel":1849},[169],[1851],{"type":34,"value":1610},{"type":21,"tag":148,"props":1853,"children":1854},{},[1855,1857,1862,1864,1869,1871],{"type":34,"value":1856},"GLP-1 receptor agonists and the risk of acute pancreatitis: a living systematic review. ",{"type":21,"tag":30,"props":1858,"children":1859},{},[1860],{"type":34,"value":1861},"medRxiv",{"type":34,"value":1863}," 2026 (",{"type":21,"tag":42,"props":1865,"children":1866},{},[1867],{"type":34,"value":1868},"preprint, pas encore relu par les pairs",{"type":34,"value":1870},"). ",{"type":21,"tag":91,"props":1872,"children":1874},{"href":620,"rel":1873},[169],[1875],{"type":34,"value":1876},"Preprint",{"type":21,"tag":148,"props":1878,"children":1879},{},[1880,1882,1887,1888,1893,1894,1899,1900],{"type":34,"value":1881},"Nassar M, et al. ",{"type":21,"tag":42,"props":1883,"children":1884},{},[1885],{"type":34,"value":1886},"GLP-1 medications may lower risk of recurrent acute pancreatitis.",{"type":34,"value":1597},{"type":21,"tag":30,"props":1889,"children":1890},{},[1891],{"type":34,"value":1892},"ENDO 2024",{"type":34,"value":207},{"type":21,"tag":42,"props":1895,"children":1896},{},[1897],{"type":34,"value":1898},"résumé de congrès",{"type":34,"value":1870},{"type":21,"tag":91,"props":1901,"children":1903},{"href":636,"rel":1902},[169],[1904],{"type":34,"value":1905},"Communiqué",{"type":21,"tag":148,"props":1907,"children":1908},{},[1909,1911,1916,1917,1922,1924],{"type":34,"value":1910},"Banks PA, et al. ",{"type":21,"tag":42,"props":1912,"children":1913},{},[1914],{"type":34,"value":1915},"Classification of acute pancreatitis — 2012: revision of the Atlanta classification.",{"type":34,"value":1597},{"type":21,"tag":30,"props":1918,"children":1919},{},[1920],{"type":34,"value":1921},"Gut",{"type":34,"value":1923}," 2013. ",{"type":21,"tag":91,"props":1925,"children":1927},{"href":658,"rel":1926},[169],[1928],{"type":34,"value":1610},{"type":21,"tag":148,"props":1930,"children":1931},{},[1932,1934,1939,1940,1945,1946],{"type":34,"value":1933},"Rinella ME, et al. ",{"type":21,"tag":42,"props":1935,"children":1936},{},[1937],{"type":34,"value":1938},"A multisociety Delphi consensus on new fatty liver disease nomenclature (MASLD).",{"type":34,"value":1597},{"type":21,"tag":30,"props":1941,"children":1942},{},[1943],{"type":34,"value":1944},"Hepatology \u002F J Hepatol",{"type":34,"value":1604},{"type":21,"tag":91,"props":1947,"children":1949},{"href":836,"rel":1948},[169],[1950],{"type":34,"value":1760},{"type":21,"tag":148,"props":1952,"children":1953},{},[1954,1956,1961,1962,1967,1968],{"type":34,"value":1955},"Samuel VT, Shulman GI. ",{"type":21,"tag":42,"props":1957,"children":1958},{},[1959],{"type":34,"value":1960},"The pathogenesis of insulin resistance.",{"type":34,"value":1597},{"type":21,"tag":30,"props":1963,"children":1964},{},[1965],{"type":34,"value":1966},"J Clin Invest",{"type":34,"value":1823},{"type":21,"tag":91,"props":1969,"children":1971},{"href":883,"rel":1970},[169],[1972],{"type":34,"value":1760},{"type":21,"tag":148,"props":1974,"children":1975},{},[1976,1977,1982,1983,1988,1990],{"type":34,"value":1955},{"type":21,"tag":42,"props":1978,"children":1979},{},[1980],{"type":34,"value":1981},"NAFLD as a Nexus of Metabolic and Hepatic Diseases.",{"type":34,"value":1597},{"type":21,"tag":30,"props":1984,"children":1985},{},[1986],{"type":34,"value":1987},"Cell Metabolism",{"type":34,"value":1989}," 2018. ",{"type":21,"tag":91,"props":1991,"children":1993},{"href":891,"rel":1992},[169],[1994],{"type":34,"value":1760},{"type":21,"tag":148,"props":1996,"children":1997},{},[1998,2000,2005,2006,2011,2012],{"type":34,"value":1999},"Buzzetti E, Pinzani M, Tsochatzis EA. ",{"type":21,"tag":42,"props":2001,"children":2002},{},[2003],{"type":34,"value":2004},"The multiple-hit pathogenesis of NAFLD.",{"type":34,"value":1597},{"type":21,"tag":30,"props":2007,"children":2008},{},[2009],{"type":34,"value":2010},"Metabolism",{"type":34,"value":1823},{"type":21,"tag":91,"props":2013,"children":2015},{"href":856,"rel":2014},[169],[2016],{"type":34,"value":1610},{"type":21,"tag":148,"props":2018,"children":2019},{},[2020,2022,2027,2028,2032,2034],{"type":34,"value":2021},"Donnelly KL, et al. ",{"type":21,"tag":42,"props":2023,"children":2024},{},[2025],{"type":34,"value":2026},"Sources of fatty acids stored in liver and secreted via lipoproteins in NAFLD.",{"type":34,"value":1597},{"type":21,"tag":30,"props":2029,"children":2030},{},[2031],{"type":34,"value":1966},{"type":34,"value":2033}," 2005. ",{"type":21,"tag":91,"props":2035,"children":2037},{"href":918,"rel":2036},[169],[2038],{"type":34,"value":1760},{"type":21,"tag":148,"props":2040,"children":2041},{},[2042,2044,2049,2050,2054,2055],{"type":34,"value":2043},"Locatelli JC, et al. ",{"type":21,"tag":42,"props":2045,"children":2046},{},[2047],{"type":34,"value":2048},"Incretin-Based Weight Loss and Resistance Exercise.",{"type":34,"value":1597},{"type":21,"tag":30,"props":2051,"children":2052},{},[2053],{"type":34,"value":1844},{"type":34,"value":1637},{"type":21,"tag":91,"props":2056,"children":2058},{"href":778,"rel":2057},[169],[2059],{"type":34,"value":2060},"Article",{"type":21,"tag":148,"props":2062,"children":2063},{},[2064,2066,2071,2072,2077,2079],{"type":34,"value":2065},"Koceva A, et al. ",{"type":21,"tag":42,"props":2067,"children":2068},{},[2069],{"type":34,"value":2070},"Impact of Incretin-Based Therapy on Skeletal Muscle Health.",{"type":34,"value":1597},{"type":21,"tag":30,"props":2073,"children":2074},{},[2075],{"type":34,"value":2076},"Medicina",{"type":34,"value":2078}," 2025. ",{"type":21,"tag":91,"props":2080,"children":2082},{"href":310,"rel":2081},[169],[2083],{"type":34,"value":1760},{"type":21,"tag":148,"props":2085,"children":2086},{},[2087,2089,2094,2095,2100,2101],{"type":34,"value":2088},"Tinsley GM, et al. ",{"type":21,"tag":42,"props":2090,"children":2091},{},[2092],{"type":34,"value":2093},"Body Composition Principles for Fat-Free and Skeletal Muscle Mass Changes.",{"type":34,"value":1597},{"type":21,"tag":30,"props":2096,"children":2097},{},[2098],{"type":34,"value":2099},"J Endocr Soc",{"type":34,"value":1637},{"type":21,"tag":91,"props":2102,"children":2104},{"href":769,"rel":2103},[169],[2105],{"type":34,"value":1760},{"type":21,"tag":148,"props":2107,"children":2108},{},[2109,2111,2116,2117,2122,2123],{"type":34,"value":2110},"do Nascimento TS, et al. ",{"type":21,"tag":42,"props":2112,"children":2113},{},[2114],{"type":34,"value":2115},"GLP-1 receptor agonists and residual gastric content (perioperative).",{"type":34,"value":1597},{"type":21,"tag":30,"props":2118,"children":2119},{},[2120],{"type":34,"value":2121},"Perioper Med",{"type":34,"value":1637},{"type":21,"tag":91,"props":2124,"children":2126},{"href":1376,"rel":2125},[169],[2127],{"type":34,"value":1760},{"type":21,"tag":148,"props":2129,"children":2130},{},[2131,2133,2138,2139,2144,2145],{"type":34,"value":2132},"Tan Y, et al. ",{"type":21,"tag":42,"props":2134,"children":2135},{},[2136],{"type":34,"value":2137},"GLP-1 receptor agonists increase residual gastric content and aspiration risk.",{"type":34,"value":1597},{"type":21,"tag":30,"props":2140,"children":2141},{},[2142],{"type":34,"value":2143},"Dig Liver Dis",{"type":34,"value":2078},{"type":21,"tag":91,"props":2146,"children":2148},{"href":1384,"rel":2147},[169],[2149],{"type":34,"value":1610},{"type":21,"tag":148,"props":2151,"children":2152},{},[2153,2155,2160,2161,2166,2167],{"type":34,"value":2154},"Ushakumari DS, et al. ",{"type":21,"tag":42,"props":2156,"children":2157},{},[2158],{"type":34,"value":2159},"ASA Consensus-based Guidance on Preoperative Management of GLP-1 RAs.",{"type":34,"value":1597},{"type":21,"tag":30,"props":2162,"children":2163},{},[2164],{"type":34,"value":2165},"Anesthesiology",{"type":34,"value":1637},{"type":21,"tag":91,"props":2168,"children":2170},{"href":1402,"rel":2169},[169],[2171],{"type":34,"value":1610},{"type":21,"tag":148,"props":2173,"children":2174},{},[2175,2177,2182,2183,2187,2188],{"type":34,"value":2176},"Jalleh RJ, et al. ",{"type":21,"tag":42,"props":2178,"children":2179},{},[2180],{"type":34,"value":2181},"Clinical Consequences of Delayed Gastric Emptying With GLP-1 RAs.",{"type":34,"value":1597},{"type":21,"tag":30,"props":2184,"children":2185},{},[2186],{"type":34,"value":1776},{"type":34,"value":1637},{"type":21,"tag":91,"props":2189,"children":2191},{"href":1393,"rel":2190},[169],[2192],{"type":34,"value":1760},{"type":21,"tag":148,"props":2194,"children":2195},{},[2196,2198,2203,2204,2209,2210],{"type":34,"value":2197},"Pachimatla AG, … Sanghvi VR, et al. ",{"type":21,"tag":42,"props":2199,"children":2200},{},[2201],{"type":34,"value":2202},"GLP-1 receptor agonism improves lung cancer outcomes and tumor immunity (obese models).",{"type":34,"value":1597},{"type":21,"tag":30,"props":2205,"children":2206},{},[2207],{"type":34,"value":2208},"JCI Insight",{"type":34,"value":2078},{"type":21,"tag":91,"props":2211,"children":2213},{"href":1511,"rel":2212},[169],[2214],{"type":34,"value":1610},{"type":21,"tag":148,"props":2216,"children":2217},{},[2218,2220,2225,2226,2230,2232],{"type":34,"value":2219},"Wilding JPH, et al. ",{"type":21,"tag":42,"props":2221,"children":2222},{},[2223],{"type":34,"value":2224},"Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1).",{"type":34,"value":1597},{"type":21,"tag":30,"props":2227,"children":2228},{},[2229],{"type":34,"value":1602},{"type":34,"value":2231}," 2021. ",{"type":21,"tag":91,"props":2233,"children":2235},{"href":1032,"rel":2234},[169],[2236],{"type":34,"value":1610},{"type":21,"tag":148,"props":2238,"children":2239},{},[2240,2242,2247,2248,2252,2253],{"type":34,"value":2241},"Jastreboff AM, et al. ",{"type":21,"tag":42,"props":2243,"children":2244},{},[2245],{"type":34,"value":2246},"Tirzepatide Once Weekly for Obesity (SURMOUNT-1).",{"type":34,"value":1597},{"type":21,"tag":30,"props":2249,"children":2250},{},[2251],{"type":34,"value":1602},{"type":34,"value":1754},{"type":21,"tag":91,"props":2254,"children":2256},{"href":1047,"rel":2255},[169],[2257],{"type":34,"value":1610},{"type":21,"tag":148,"props":2259,"children":2260},{},[2261,2263,2268,2269,2274,2275],{"type":34,"value":2262},"Holst JJ. ",{"type":21,"tag":42,"props":2264,"children":2265},{},[2266],{"type":34,"value":2267},"GLP-1 physiology in obesity and incretin-based drugs.",{"type":34,"value":1597},{"type":21,"tag":30,"props":2270,"children":2271},{},[2272],{"type":34,"value":2273},"Nature Metabolism",{"type":34,"value":1637},{"type":21,"tag":91,"props":2276,"children":2278},{"href":1056,"rel":2277},[169],[2279],{"type":34,"value":1610},{"type":21,"tag":148,"props":2281,"children":2282},{},[2283,2285,2290,2291,2296,2297],{"type":34,"value":2284},"Nauck MA, et al. ",{"type":21,"tag":42,"props":2286,"children":2287},{},[2288],{"type":34,"value":2289},"The evolving story of incretins (GIP and GLP-1).",{"type":34,"value":1597},{"type":21,"tag":30,"props":2292,"children":2293},{},[2294],{"type":34,"value":2295},"Diabetes Obes Metab",{"type":34,"value":2231},{"type":21,"tag":91,"props":2298,"children":2300},{"href":1064,"rel":2299},[169],[2301],{"type":34,"value":2060},{"type":21,"tag":148,"props":2303,"children":2304},{},[2305,2307,2312,2314],{"type":34,"value":2306},"California Board of Chiropractic Examiners. ",{"type":21,"tag":42,"props":2308,"children":2309},{},[2310],{"type":34,"value":2311},"Documents de séance, 29 oct. 2020",{"type":34,"value":2313}," (licence DC 29377, révoquée le 8 juillet 2020). ",{"type":21,"tag":91,"props":2315,"children":2317},{"href":167,"rel":2316},[169],[2318],{"type":34,"value":2319},"PDF",{"type":21,"tag":148,"props":2321,"children":2322},{},[2323,2324,2329,2330],{"type":34,"value":2306},{"type":21,"tag":42,"props":2325,"children":2326},{},[2327],{"type":34,"value":2328},"Sanctions disciplinaires définitives.",{"type":34,"value":1597},{"type":21,"tag":91,"props":2331,"children":2333},{"href":382,"rel":2332},[169],[2334],{"type":34,"value":2335},"Page",{"type":21,"tag":148,"props":2337,"children":2338},{},[2339,2341,2346,2347],{"type":34,"value":2340},"California Department of Consumer Affairs. ",{"type":21,"tag":42,"props":2342,"children":2343},{},[2344],{"type":34,"value":2345},"Recherche de licence.",{"type":34,"value":1597},{"type":21,"tag":91,"props":2348,"children":2350},{"href":391,"rel":2349},[169],[2351],{"type":34,"value":2352},"Recherche",{"type":21,"tag":148,"props":2354,"children":2355},{},[2356,2358,2363,2364],{"type":34,"value":2357},"EliteBiogenix. ",{"type":21,"tag":42,"props":2359,"children":2360},{},[2361],{"type":34,"value":2362},"Vendeur de peptides de recherche et de SARM (recherche in vitro uniquement).",{"type":34,"value":1597},{"type":21,"tag":91,"props":2365,"children":2367},{"href":177,"rel":2366},[169],[2368],{"type":34,"value":2369},"Site",{"type":21,"tag":148,"props":2371,"children":2372},{},[2373,2375,2380,2381,2386,2387],{"type":34,"value":2374},"Bachmeyer T. ",{"type":21,"tag":42,"props":2376,"children":2377},{},[2378],{"type":34,"value":2379},"\"Mega Dosing vs Micro Dosing Retatrutide: Which Damages Your Liver More?\"",{"type":34,"value":1597},{"type":21,"tag":30,"props":2382,"children":2383},{},[2384],{"type":34,"value":2385},"YouTube.",{"type":34,"value":1597},{"type":21,"tag":91,"props":2388,"children":2391},{"href":2389,"rel":2390},"https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=gb-XEtsMr-w",[169],[2392],{"type":34,"value":2393},"Vidéo",{"title":7,"searchDepth":2395,"depth":2395,"links":2396},2,[2397,2398,2399,2400,2401,2402,2403,2404,2405,2406,2407,2408,2409,2410,2411,2412,2413,2414,2415],{"id":127,"depth":2395,"text":130},{"id":330,"depth":2395,"text":333},{"id":419,"depth":2395,"text":422},{"id":482,"depth":2395,"text":485},{"id":563,"depth":2395,"text":566},{"id":667,"depth":2395,"text":670},{"id":733,"depth":2395,"text":736},{"id":787,"depth":2395,"text":790},{"id":807,"depth":2395,"text":810},{"id":818,"depth":2395,"text":821},{"id":872,"depth":2395,"text":875},{"id":934,"depth":2395,"text":937},{"id":1014,"depth":2395,"text":1017},{"id":1353,"depth":2395,"text":1356},{"id":1417,"depth":2395,"text":1420},{"id":1462,"depth":2395,"text":1465},{"id":1500,"depth":2395,"text":1503},{"id":1520,"depth":2395,"text":1523},{"id":1578,"depth":2395,"text":1581},"markdown","content:blog:fr:retatrutide-liver-damage-myths.md","content","blog\u002Ffr\u002Fretatrutide-liver-damage-myths.md","blog\u002Ffr\u002Fretatrutide-liver-damage-myths","md"]